Medytox (Exclusive Right To Develop Neurotoxin Products) Overview

  • Status
  • Acquired/​Merged
  • Latest Deal Type
  • Asset Purch.
  • Financing Rounds
  • 1

Medytox (Exclusive Right To Develop Neurotoxin Products) General Information

Description

Portfolio of rights to commercialize neurotoxin products. The portfolio provides exclusive rights, outside of Korea, and co-exclusive rights in Japan, to develop and commercialize certain neurotoxin product candidates including a potential liquid-injectable product.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Buildings and Property
Other Industries
Other Business Products and Services
Acquirer
Primary Office
  • 78, Gagni 1-Gil, Ochang-Eup
  • Cheongwon-Gu, Chungcheongbuk-Do
  • Cheongju, 363-883
  • South Korea
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Medytox (Exclusive Right To Develop Neurotoxin Products) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Medytox (Exclusive Right To Develop Neurotoxin Products)‘s full profile, request access.

Request a free trial

Medytox (Exclusive Right To Develop Neurotoxin Products) Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Medytox (Exclusive Right To Develop Neurotoxin Products)‘s full profile, request access.

Request a free trial